Q3 EPS Estimate for Compass Therapeutics Lowered by Analyst

Compass Therapeutics, Inc. (NASDAQ:CMPX) – Analysts at HC Wainwright reduced their Q3 2026 earnings per share estimates for shares of Compass Therapeutics in a research report issued to clients and investors on Thursday, August 6th. HC Wainwright analyst J. Pantginis now expects that the company will earn ($0.15) per share for the quarter, down from their prior estimate of ($0.11). HC Wainwright currently has a “Buy” rating and a $24.00 price objective on the stock. The consensus estimate for Compass Therapeutics’ current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Compass Therapeutics’ Q4 2026 earnings at ($0.17) EPS, FY2026 earnings at ($0.55) EPS, FY2027 earnings at ($0.56) EPS and FY2028 earnings at ($0.56) EPS.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02).

CMPX has been the subject of several other reports. LADENBURG THALM/SH SH assumed coverage on shares of Compass Therapeutics in a research note on Wednesday, July 1st. They issued a “buy” rating and a $5.00 price target for the company. Raymond James Financial cut shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, April 28th. Wall Street Zen downgraded Compass Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday. Citigroup reaffirmed a “market outperform” rating on shares of Compass Therapeutics in a research report on Thursday, June 4th. Finally, Piper Sandler upped their price target on Compass Therapeutics from $4.00 to $6.00 and gave the stock an “overweight” rating in a research note on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Compass Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $11.77.

Compass Therapeutics Trading Down 0.9%

NASDAQ:CMPX opened at $2.20 on Monday. The stock has a market capitalization of $396.20 million, a price-to-earnings ratio of -5.50 and a beta of 0.92. The firm has a fifty day simple moving average of $2.09 and a two-hundred day simple moving average of $3.80. Compass Therapeutics has a 12 month low of $1.61 and a 12 month high of $6.88.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Ieq Capital LLC bought a new position in shares of Compass Therapeutics in the second quarter valued at $269,000. E Fund Management Co. Ltd. bought a new stake in shares of Compass Therapeutics during the second quarter worth about $59,000. BlackRock Inc. bought a new stake in shares of Compass Therapeutics during the second quarter worth about $24,707,000. Deutsche Bank AG bought a new stake in shares of Compass Therapeutics during the second quarter worth about $294,000. Finally, Simplicity Wealth LLC acquired a new stake in shares of Compass Therapeutics in the 2nd quarter worth about $80,000. Institutional investors and hedge funds own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical?stage biotechnology company dedicated to the discovery and development of novel immuno?oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti?tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47?SIRP? pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.